I
Iain MacPhee
Researcher at St George's, University of London
Publications - 98
Citations - 4025
Iain MacPhee is an academic researcher from St George's, University of London. The author has contributed to research in topics: Transplantation & Tacrolimus. The author has an hindex of 28, co-authored 98 publications receiving 3461 citations. Previous affiliations of Iain MacPhee include St George's Hospital & University of Oxford.
Papers
More filters
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Kelly A. Birdwell,Brian S. Decker,Julia M. Barbarino,Josh F. Peterson,Charles M. Stein,Wolfgang Sadee,Danxin Wang,Alexander A. Vinks,Yijing He,Jesse J. Swen,J. S. Leeder,Ron H.N. van Schaik,Kenneth E. Thummel,Teri E. Klein,Kelly E. Caudle,Iain MacPhee +15 more
TL;DR: Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation as discussed by the authors, however, individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacromin as compared with those who are CYP 3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Kelly A. Birdwell,Brian Decker,Julia M. Barbarino,Josh F. Peterson,C. Michael Stein,Wolfgang Sadee,Danxin Wang,Alexander A. Vinks,Yijing He,Jesse J. Swen,J. Steven Leeder,Rhn van Schaik,Kenneth E. Thummel,Teri E. Klein,Kelly E. Caudle,Iain MacPhee +15 more
TL;DR: Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP 3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations.
Journal ArticleDOI
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report
Mercè Brunet,Teun van Gelder,Anders Åsberg,Vincent Haufroid,Vincent Haufroid,Dennis A. Hesselink,Loralie J. Langman,Florian Lemaitre,Pierre Marquet,Christoph Seger,Maria Shipkova,Alexander A. Vinks,Alexander A. Vinks,Pierre Wallemacq,Eberhard Wieland,Jean-Baptiste Woillard,Markus J. Barten,Klemens Budde,Helena Colom,Maja Theresa Dieterlen,Laure Elens,Kamisha L. Johnson-Davis,Paweł K. Kunicki,Iain MacPhee,Satohiro Masuda,Binu S. Mathew,Olga Millán,Tomoyuki Mizuno,Tomoyuki Mizuno,Dirk Jan A.R. Moes,Caroline Monchaud,Ofelia Noceti,Tomasz Pawinski,Nicolas Picard,Ron H.N. van Schaik,Claudia Sommerer,Nils Tore Vethe,Brenda C. M. de Winter,Uwe Christians,Stein Bergan +39 more
TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.
Journal ArticleDOI
Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids
TL;DR: It is concluded that endogenous corticosterone release in rats with EAE plays an essential role in the spontaneous recovery that is observed in this condition, and the subsequent refractory phase that is characteristic of rats that have recovered from EAE induced by active immunization with MBP is not associated with chronically elevated cortic testosterone levels.
Journal ArticleDOI
Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
Iain MacPhee,Salim Fredericks,Tracy Tai,Petros Syrris,Nicholas D. Carter,Atholl Johnston,Lawrence Goldberg,David W. Holt +7 more
TL;DR: The CYP3AP1 genotype is a major factor in determining the dose requirement for tacrolimus, and genotyping may be of value in planning patient-specific drug dosing.